CL2022001337A1 - Derivados de piridopirimidinona como antagonistas de ahr - Google Patents
Derivados de piridopirimidinona como antagonistas de ahrInfo
- Publication number
- CL2022001337A1 CL2022001337A1 CL2022001337A CL2022001337A CL2022001337A1 CL 2022001337 A1 CL2022001337 A1 CL 2022001337A1 CL 2022001337 A CL2022001337 A CL 2022001337A CL 2022001337 A CL2022001337 A CL 2022001337A CL 2022001337 A1 CL2022001337 A1 CL 2022001337A1
- Authority
- CL
- Chile
- Prior art keywords
- same
- preparing
- compounds
- treatment
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente divulgación se refiere a compuestos de Fórmula (Ia) y sales farmacéuticamente aceptables de los mismos, a composiciones farmacéuticas que comprenden los mismos, a métodos para preparar los mismos, a compuestos intermedios útiles para preparar los mismos y a métodos para el tratamiento o la profilaxis de enfermedades, en particular cáncer o afecciones con respuestas inmunitarias desreguladas u otros trastornos asociados con una señalización aberrante de AHR. Estos compuestos también pueden ser útiles en el tratamiento del cáncer cuando se administran en combinación con al menos una terapia adicional.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962939377P | 2019-11-22 | 2019-11-22 | |
US202063050416P | 2020-07-10 | 2020-07-10 | |
US202063091192P | 2020-10-13 | 2020-10-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2022001337A1 true CL2022001337A1 (es) | 2023-05-05 |
Family
ID=73854915
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2022001337A CL2022001337A1 (es) | 2019-11-22 | 2022-05-20 | Derivados de piridopirimidinona como antagonistas de ahr |
Country Status (13)
Country | Link |
---|---|
US (1) | US20230295152A1 (es) |
EP (1) | EP4061484A1 (es) |
JP (1) | JP2023502476A (es) |
KR (1) | KR20220119537A (es) |
CN (1) | CN115397512A (es) |
AU (1) | AU2020386967A1 (es) |
BR (1) | BR112022009805A2 (es) |
CA (1) | CA3162236A1 (es) |
CL (1) | CL2022001337A1 (es) |
CO (1) | CO2022008606A2 (es) |
IL (1) | IL293103A (es) |
MX (1) | MX2022006086A (es) |
WO (1) | WO2021102288A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20230147257A1 (en) * | 2020-04-17 | 2023-05-11 | Dong-A St Co., Ltd. | Pyridopyrimidinone derivatives and their use as aryl hydrocarbon receptor modulators |
US20230381182A1 (en) | 2020-10-13 | 2023-11-30 | Senda Biosciences, Inc. | Biomarkers Related to Immune Checkpoint Inhibitor Therapy and Methods of Using the Same |
CN114644627B (zh) * | 2020-12-18 | 2024-06-11 | 山东轩竹医药科技有限公司 | AhR抑制剂及其用途 |
WO2022217042A1 (en) * | 2021-04-09 | 2022-10-13 | Ikena Oncology, Inc. | Naphthyl-substituted quinoline-4(1h)-ones and related compounds and their use in treating medical conditions |
CN115093400B (zh) * | 2021-09-18 | 2023-09-05 | 北京华森英诺生物科技有限公司 | AhR抑制剂及其用途和制备方法 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2846657B1 (fr) * | 2002-11-05 | 2004-12-24 | Servier Lab | Nouveaux composes pyridopyrimidinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
MX2019012431A (es) * | 2017-04-21 | 2020-08-03 | Ikena Oncology Inc | Inhibidores del receptor de hidrocarburos de arilo (ahr) de indol y usos de los mismos. |
EP3749669B1 (en) * | 2018-02-06 | 2023-03-08 | Ideaya Biosciences, Inc. | Ahr modulators |
CN111961034A (zh) * | 2019-05-20 | 2020-11-20 | 浙江同源康医药股份有限公司 | 用作ret激酶抑制剂的化合物及其应用 |
US20230147257A1 (en) * | 2020-04-17 | 2023-05-11 | Dong-A St Co., Ltd. | Pyridopyrimidinone derivatives and their use as aryl hydrocarbon receptor modulators |
-
2020
- 2020-11-20 WO PCT/US2020/061548 patent/WO2021102288A1/en unknown
- 2020-11-20 CN CN202080096897.6A patent/CN115397512A/zh active Pending
- 2020-11-20 CA CA3162236A patent/CA3162236A1/en active Pending
- 2020-11-20 JP JP2022529544A patent/JP2023502476A/ja active Pending
- 2020-11-20 AU AU2020386967A patent/AU2020386967A1/en active Pending
- 2020-11-20 US US17/756,243 patent/US20230295152A1/en active Pending
- 2020-11-20 IL IL293103A patent/IL293103A/en unknown
- 2020-11-20 KR KR1020227021077A patent/KR20220119537A/ko unknown
- 2020-11-20 BR BR112022009805A patent/BR112022009805A2/pt unknown
- 2020-11-20 MX MX2022006086A patent/MX2022006086A/es unknown
- 2020-11-20 EP EP20825321.1A patent/EP4061484A1/en active Pending
-
2022
- 2022-05-20 CL CL2022001337A patent/CL2022001337A1/es unknown
- 2022-06-17 CO CONC2022/0008606A patent/CO2022008606A2/es unknown
Also Published As
Publication number | Publication date |
---|---|
US20230295152A1 (en) | 2023-09-21 |
CO2022008606A2 (es) | 2022-09-20 |
BR112022009805A2 (pt) | 2022-08-16 |
CA3162236A1 (en) | 2021-05-27 |
KR20220119537A (ko) | 2022-08-29 |
EP4061484A1 (en) | 2022-09-28 |
IL293103A (en) | 2022-07-01 |
AU2020386967A1 (en) | 2022-07-07 |
CN115397512A (zh) | 2022-11-25 |
MX2022006086A (es) | 2022-09-07 |
JP2023502476A (ja) | 2023-01-24 |
WO2021102288A1 (en) | 2021-05-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2022001337A1 (es) | Derivados de piridopirimidinona como antagonistas de ahr | |
ECSP20067394A (es) | Inhibidores de cinasa dependientes de ciclina | |
CO2019007810A2 (es) | Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer | |
ECSP21055158A (es) | Compuestos de 3-carbonilamino-5-ciclopentil-1h-pirazol que tienen actividad inhibitoria sobre cdk2 | |
NI202000099A (es) | Compuestos de purinona y su uso en el tratamiento del cáncer | |
CO2018003969A2 (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona | |
DOP2013000263A (es) | Compuestos de 2- (2,4,5-anilino sustituido) pirimidina derivados como moduladores de egfr utilizados para el tratamiento del cáncer | |
CU20170154A7 (es) | Derivados de pirazol-3-il-amina sustituidos como inhibidores cdk | |
CL2020001097A1 (es) | Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
DOP2018000115A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso en el tratamiento del cáncer | |
CL2009000780A1 (es) | Compuestos derivados de heterociclil-pirano-heterociclilo, heterociclil-oxepina-heterociclilo, benzopirano-heterociclilo y benzoxepina-heterociclilo sustituidos; composicion farmaceutica; procedimiento de preparacion de la composicion; kit farmaceutico; y su uso en el tratamiento del cancer, mediado por la inhibicion de pi3k. | |
NI201000145A (es) | DERIVADOS DE IMIDAZO - [1, 2-b] - PIRIDAZINA PARA EL TRATAMIENTO DE ENFERMEDAD MEDIADA POR CINASA DE TIROSINA C-MET. | |
CO2019007409A2 (es) | Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos | |
NI201900094A (es) | COMPUESTOS DE TIPO IMIDAZO[4, 5-c]QUINOLIN-2-ONA DEUTERADOS Y SU USO EN EL TRATAMIENTO DEL CÁNCER | |
PH12019502150A1 (en) | Compounds and methods for the treatment of parasitic diseases | |
CL2021003034A1 (es) | Métodos de tratamiento del síndrome de sjögren utilizando un inhibidor de la tirosina quinasa de bruton | |
UY32829A (es) | Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo | |
DOP2019000299A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
CL2021000184A1 (es) | Piridopirimidinas como inhibidores del receptor de histamina h4 | |
CY1123185T1 (el) | Παραγωγα ινδολιου | |
AR120158A2 (es) | Derivados de indol mono o di sustituidos como inhibidores de la replicación viral del dengue | |
AR105921A1 (es) | Compuestos terapéuticos para el dolor y síntesis de estos |